Advanced Renal Cell Carcinoma: Nivolumab/Ipilimumab Improves Treatment-Free Survival

Nivolumab/ipilimumab prolongs treatment-free survival with and without toxicity in patients with untreated advanced renal cell carcinoma (RCC), according to an updated analysis of the phase 3 CheckMate 214 trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. "Conventional measures may not fully characterize the impact of immuno-oncology agents," comment the investigators in their presentation abstract, led by first author Meredith Regan, ScD, Associate Profe...
Continue reading

Atezolizumab Combo Effective in EGFR-Mutated Non-Small Cell Lung Cancer

The addition of atezolizumab to bevacizumab/carboplatin/paclitaxel (BCP) significantly prolongs overall survival in patients with non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, according to results of a final efficacy analysis presented this week at the European Medical Society for Oncology (ESMO) Virtual Congress 2020. "Atezolizumab inhibits programmed death-ligand 1 (PD-L1) to restore anti-cancer immunity; bevacizumab may enhance atezoli...
Continue reading

DLBCL: Complete Surgical Resection Before Immunochemotherapy May Benefit Younger Patients

Complete surgical resection prior to immunochemotherapy may benefit patients with diffuse large B-cell lymphoma (DLBCL) under the age of 60, according to results from a subgroup analysis of the phase 3 PETAL trial. Unlike the treatment of solid tumors, the treatment of lymphoma focuses almost exclusively on systemic therapy. Surgical resection is generally only performed for diagnostic value, and little evidence exists regarding its impact on outcomes for patients with lymphoma. "Modern imaging ...
Continue reading

FDA Alert: Atezolizumab/Paclitaxel Ineffective for Triple-Negative Breast Cancer

The FDA has issued an alert regarding the combination of atezolizumab (Tecentriq®, Genentech) and paclitaxel for the treatment of patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer (TNBC). In addition to being ineffective, atezolizumab/paclitaxel can negatively impact overall survival. While atezolizumab/paclitaxel is not approved for the treatment of breast cancer, atezolizumab in combination with paclitaxel protein-bound particles, also ...
Continue reading

Neoadjuvant Nivolumab/Ipilimumab for Oral Cavity SCC: Jonathan Schoenfeld, MD, MPH

Due to intensive treatments, severe side effects, and a high rate of recurrence, oral cavity squamous cell carcinoma (SCC) is a challenging disease associated with poor outcomes. According to a recent study, neoadjuvant nivolumab alone or in combination with ipilimumab may be a safe and effective treatment for patients with oral cavity SCC undergoing surgical resection. In this interview, Jonathan Schoenfeld, MD, MPH, Associate Professor of Radiation Oncology at Harvard Medical School and first ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.